Kura Oncology Statistics

Total Valuation

Kura Oncology has a market cap or net worth of $1.57 billion. The enterprise value is $1.06 billion.

Market Cap	1.57B
Enterprise Value	1.06B

Important Dates

The next estimated earnings date is Thursday, August 1, 2024, after market close.

Earnings Date	Aug 1, 2024
Ex-Dividend Date	n/a

Share Statistics

Kura Oncology has 76.18 million shares outstanding. The number of shares has increased by 22.66% in one year.

Shares Outstanding	76.18M
Shares Change (YoY)	+22.66%
Shares Change (QoQ)	+8.43%
Owned by Insiders (%)	1.07%
Owned by Institutions (%)	109.15%
Float	48.62M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.10
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 16.67, with a Debt / Equity ratio of 0.03.

Current Ratio	16.67
Quick Ratio	n/a
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-105.18

Financial Efficiency

Return on equity (ROE) is -37.50% and return on invested capital (ROIC) is -35.19%.

Return on Equity (ROE)	-37.50%
Return on Assets (ROA)	-34.10%
Return on Capital (ROIC)	-35.19%
Revenue Per Employee	n/a
Profits Per Employee	-$1.18M
Employee Count	142
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +94.15% in the last 52 weeks. The beta is 0.94, so Kura Oncology's price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	+94.15%
50-Day Moving Average	20.83
200-Day Moving Average	16.21
Relative Strength Index (RSI)	47.29
Average Volume (20 Days)	840,279

Short Selling Information

The latest short interest is 9.84 million, so 12.92% of the outstanding shares have been sold short.

Short Interest	9.84M
Short Previous Month	9.88M
Short % of Shares Out	12.92%
Short % of Float	20.25%
Short Ratio (days to cover)	15.92

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-183.69M
Pretax Income	-168.09M
Net Income	-168.09M
EBITDA	-165.63M
EBIT	-166.50M
Earnings Per Share (EPS)	-$2.17

Full Income Statement

Balance Sheet

The company has $527.12 million in cash and $16.97 million in debt, giving a net cash position of $510.15 million or $6.70 per share.

Cash & Cash Equivalents	527.12M
Total Debt	16.97M
Net Cash	510.15M
Net Cash Per Share	$6.70
Equity (Book Value)	505.08M
Book Value Per Share	6.63
Working Capital	505.57M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$137.80 million and capital expenditures -$216,000, giving a free cash flow of -$138.01 million.

Operating Cash Flow	-137.80M
Capital Expenditures	-216,000
Free Cash Flow	-138.01M
FCF Per Share	-$1.65

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kura Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.66%
Shareholder Yield	-22.66%
Earnings Yield	-10.72%
FCF Yield	-8.80%

Analyst Forecast

The average price target for Kura Oncology is $28.36, which is 37.80% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$28.36
Price Target Difference	37.80%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1